Rituximab Therapy For The Induction Of Remission And Tolerance In ANCA-Associated Vasculitis

Kyriakos A. Kirou, MD
Jonathan Samuels, MD

Summary

200 participants nationwide 30 months
Study Duration: The common closing date will be 18 months after the last participant is enrolled.
Primary Objective: determine the efficacy of Rituximab (four weekly infusions) and glucocorticoids in the induction of remission of WG

Inclusion/Exclusion Criteria

Inclusion Criteria

Potential participants must meet all of the following:

1. Age: They must be over 15 years of age.
2. Weight: They must weigh at least 40 kg.
3. Diagnosis type: They must be diagnosed with WG or MPA
4. Screening diagnosis: They must be newly diagnosed patients, or they must have a disease flare

Exclusion Criteria

Potential participants with any of the following will NOT be enrolled in this study:

1. Diagnosis: They are diagnosed with Churg Strauss syndrome
2. Limited disease: They have limited disease that would not normally be treated with CYC.
3. Severe disease: They require mechanical ventilation because of alveolar hemorrhage.
4. Infection (systemic): They have an active systemic infection, active hepatitis B or active hepatitis C or a documented history of HIV, hepatitis B, or hepatitis C.

Contact Information

Stacey Kloiber, RN
212.774.7194